Summary
Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H2 2016’, provides an overview of the Diabetic Macular Edema pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aciont Inc.
ActiveSite Pharmaceuticals, Inc.
Adverum Biotechnologies, Inc.
Aerpio Therapeutics, Inc.
Allergan Plc
Ampio Pharmaceuticals, Inc.
Araim Pharmaceuticals, Inc.
Astellas Pharma Inc.
Boehringer Ingelheim GmbH
Chengdu Kanghong Pharmaceuticals G
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Macular Edema - Overview 10
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 11
Diabetic Macular Edema - Therapeutics under Development by Companies 12
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 16
Diabetic Macular Edema - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Macular Edema - Products under Development by Companies 21
Diabetic Macular Edema - Products under Investigation by Universities/Institutes 24
Diabetic Macular Edema - Companies Involved in Therapeutics Development 25
Aciont Inc. 25
ActiveSite Pharmaceuticals, Inc. 26
Adverum Biotechnologies, Inc. 27
Aerpio Therapeutics, Inc. 28
Allergan Plc 29
Ampio Pharmaceuticals, Inc. 30
Araim Pharmaceuticals, Inc. 31
Astellas Pharma Inc. 32
Boehringer Ingelheim GmbH 33
Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 34
Clonz Biotech Private Limited 35
7 Coherus BioSciences, Inc. 36
EyeGate Pharmaceuticals, Inc. 37
EyeGene, Inc. 38
F. Hoffmann-La Roche Ltd. 39
Formycon AG 40
Genmab A/S 41
Icon Bioscience, Inc. 42
Kala Pharmaceuticals, Inc. 43
Kalvista Pharmaceuticals Ltd 44
Kowa Company, Ltd. 45
Mabion SA 46
NicOx S.A. 47
Oculis ehf 48
Ohr Pharmaceutical Inc. 49
Pfizer Inc. 50
Precision Ocular Ltd 51
pSivida Corp. 52
Regeneron Pharmaceuticals, Inc. 53
Santen Pharmaceutical Co., Ltd. 54
SciFluor Life Sciences, LLC 55
Senju Pharmaceutical Co., Ltd. 56
Stealth BioTherapeutics Inc. 57
Sucampo Pharmaceuticals, Inc. 58
ThromboGenics NV 59
Verseon Corporation 60
Xbrane Biopharma AB 61
Diabetic Macular Edema - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(aflibercept + nesvacumab) - Drug Profile 74
abicipar pegol - Drug Profile 75
ACX-107 - Drug Profile 78
aflibercept biosimilar - Drug Profile 79
AKB-9778 - Drug Profile 80
ALG-1001 - Drug Profile 84
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 87
ASP-440 - Drug Profile 88
ASP-8232 - Drug Profile 89
ASPPDC-010 - Drug Profile 90
AVA-101 - Drug Profile 91
BI-1026706 - Drug Profile 94
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 95
cibinetide - Drug Profile 96
conbercept - Drug Profile 99
danazol - Drug Profile 101
dexamethasone acetate - Drug Profile 105
dexamethasone acetate - Drug Profile 109
dexamethasone dipropionate - Drug Profile 110
dexamethasone dipropionate XR - Drug Profile 111
difluprednate - Drug Profile 112
Drug for Diabetic Macular Edema - Drug Profile 113
Drugs for Retinal Diseases - Drug Profile 114
EBI-031 - Drug Profile 115
EG-Mirotin - Drug Profile 116
elamipretide - Drug Profile 117
fluocinolone acetonide SR - Drug Profile 124
JDE-006 - Drug Profile 132
KVD-001 - Drug Profile 133
loteprednol etabonate - Drug Profile 134
NCX-422 - Drug Profile 137
NCX-434 - Drug Profile 138
NM-108 - Drug Profile 140
OLX-303 - Drug Profile 141
PF-655 - Drug Profile 142
ranibizumab biosimilar - Drug Profile 145
ranibizumab biosimilar - Drug Profile 146
ranibizumab biosimilar - Drug Profile 148
ranibizumab biosimilar - Drug Profile 149
ranibizumab biosimilar - Drug Profile 150
RC-1 Alpha - Drug Profile 151
ripasudil - Drug Profile 152
RTU-1096 - Drug Profile 154
SF-0166 - Drug Profile 156
Small Molecule for Diabetic Macular Edema - Drug Profile 157
Small Molecule to Inhibit Kallikrein for Diabetic Macular Edema - Drug Profile 158
Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 159
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 160
squalamine lactate - Drug Profile 162
teprotumumab - Drug Profile 170
TG-931 - Drug Profile 172
THR-149 - Drug Profile 173
triamcinolone acetonide - Drug Profile 174
VA-999272 - Drug Profile 175
Diabetic Macular Edema - Dormant Projects 176
Diabetic Macular Edema - Discontinued Products 179
Diabetic Macular Edema - Product Development Milestones 180
Featured News & Press Releases 180
Appendix 190
Methodology 190
Coverage 190
Secondary Research 190
Primary Research 190
Expert Panel Validation 190
Contact Us 190
Disclaimer 191
List of Tables
Number of Products under Development for Diabetic Macular Edema, H2 2016 14
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2016 28
Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2016 29
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016 30
Diabetic Macular Edema - Pipeline by Adverum Biotechnologies, Inc., H2 2016 31
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2016 32
Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2016 33
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 34
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 35
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2016 36
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2016 37
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2016 38
Diabetic Macular Edema - Pipeline by Clonz Biotech Private Limited, H2 2016 39
Diabetic Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016 40
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 41
Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2016 42
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 43
Diabetic Macular Edema - Pipeline by Formycon AG, H2 2016 44
Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2016 45
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2016 46
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 47
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H2 2016 48
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2016 49
Diabetic Macular Edema - Pipeline by Mabion SA, H2 2016 50
Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2016 51
Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2016 52
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2016 53
Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2016 54
Diabetic Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016 55
Diabetic Macular Edema - Pipeline by pSivida Corp., H2 2016 56
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 57
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 58
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2016 59
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 60
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc., H2 2016 61
Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 62
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2016 63
Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2016 64
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016 65
Assessment by Monotherapy Products, H2 2016 66
Assessment by Combination Products, H2 2016 67
Number of Products by Stage and Target, H2 2016 69
Number of Products by Stage and Mechanism of Action, H2 2016 72
Number of Products by Stage and Route of Administration, H2 2016 75
Number of Products by Stage and Molecule Type, H2 2016 77
Diabetic Macular Edema - Dormant Projects, H2 2016 180
Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2016 181
Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2016 182
Diabetic Macular Edema - Discontinued Products, H2 2016 183
List of Figures
Number of Products under Development for Diabetic Macular Edema, H2 2016 14
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 66
Number of Products by Top 10 Targets, H2 2016 68
Number of Products by Stage and Top 10 Targets, H2 2016 68
Number of Products by Top 10 Mechanism of Actions, H2 2016 71
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 71
Number of Products by Routes of Administration, H2 2016 74
Number of Products by Stage and Routes of Administration, H2 2016 74
Number of Products by Molecule Types, H2 2016 76
Number of Products by Stage and Molecule Types, H2 2016 76
